Johnson & Johnson Total Current Assets 2010-2024 | JNJ
Johnson & Johnson total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Johnson & Johnson total current assets for the quarter ending June 30, 2024 were $57.817B, a 4.54% decline year-over-year.
- Johnson & Johnson total current assets for 2023 were $53.495B, a 3.25% decline from 2022.
- Johnson & Johnson total current assets for 2022 were $55.294B, a 9.32% decline from 2021.
- Johnson & Johnson total current assets for 2021 were $60.979B, a 19.01% increase from 2020.
Johnson & Johnson Annual Total Current Assets
(Millions of US $) |
| 2023 |
$53,495 |
| 2022 |
$55,294 |
| 2021 |
$60,979 |
| 2020 |
$51,237 |
| 2019 |
$45,274 |
| 2018 |
$46,033 |
| 2017 |
$43,088 |
| 2016 |
$65,032 |
| 2015 |
$60,210 |
| 2014 |
$55,744 |
| 2013 |
$56,407 |
| 2012 |
$46,116 |
| 2011 |
$54,316 |
| 2010 |
$47,307 |
| 2009 |
$39,541 |
Johnson & Johnson Quarterly Total Current Assets
(Millions of US $) |
| 2024-06-30 |
$57,817 |
| 2024-03-31 |
$57,002 |
| 2023-12-31 |
$53,495 |
| 2023-09-30 |
$53,703 |
| 2023-06-30 |
$60,567 |
| 2023-03-31 |
$64,388 |
| 2022-12-31 |
$55,294 |
| 2022-09-30 |
$65,236 |
| 2022-06-30 |
$63,847 |
| 2022-03-31 |
$60,424 |
| 2021-12-31 |
$60,979 |
| 2021-09-30 |
$59,889 |
| 2021-06-30 |
$53,769 |
| 2021-03-31 |
$52,533 |
| 2020-12-31 |
$51,237 |
| 2020-09-30 |
$57,578 |
| 2020-06-30 |
$45,892 |
| 2020-03-31 |
$44,226 |
| 2019-12-31 |
$45,274 |
| 2019-09-30 |
$44,333 |
| 2019-06-30 |
$41,799 |
| 2019-03-31 |
$41,987 |
| 2018-12-31 |
$46,033 |
| 2018-09-30 |
$47,194 |
| 2018-06-30 |
$45,438 |
| 2018-03-31 |
$42,768 |
| 2017-12-31 |
$43,088 |
| 2017-09-30 |
$41,829 |
| 2017-06-30 |
$38,789 |
| 2017-03-31 |
$63,347 |
| 2016-12-31 |
$65,032 |
| 2016-09-30 |
$63,319 |
| 2016-06-30 |
$66,291 |
| 2016-03-31 |
$62,738 |
| 2015-12-31 |
$60,210 |
| 2015-09-30 |
$63,494 |
| 2015-06-30 |
$61,001 |
| 2015-03-31 |
$58,192 |
| 2014-12-31 |
$55,744 |
| 2014-09-30 |
$59,973 |
| 2014-06-30 |
$60,119 |
| 2014-03-31 |
$57,369 |
| 2013-12-31 |
$56,407 |
| 2013-09-30 |
$52,176 |
| 2013-06-30 |
$51,273 |
| 2013-03-31 |
$47,228 |
| 2012-12-31 |
$46,116 |
| 2012-09-30 |
$44,791 |
| 2012-06-30 |
$41,615 |
| 2012-03-31 |
$57,007 |
| 2011-12-31 |
$54,316 |
| 2011-09-30 |
$53,443 |
| 2011-06-30 |
$52,673 |
| 2011-03-31 |
$49,221 |
| 2010-12-31 |
$47,307 |
| 2010-09-30 |
$42,717 |
| 2010-06-30 |
$39,023 |
| 2010-03-31 |
$38,861 |
| 2009-12-31 |
$39,541 |
| 2009-09-30 |
$35,602 |
| 2009-06-30 |
$35,494 |
| 2009-03-31 |
$34,839 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.964B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
